About
Genuine Biotech Limited is facing a significant decline in revenue and tight cash flow due to the waning market demand for its core product Azvudine and the termination of its cooperation with FOSUN PHARMA, under pressure from a listing bet agreement. The company applied for a listing on the Hong Kong Stock Exchange for the third time in November 2025, after two previous applications were unsuccessful. Azvudine needs to complete confirmatory clinical research before 2026
WuXi AppTec has been awarded Frost & Sullivan's 2025 Global Company of the Year Award in the CRDMO industry for the ninth consecutive year. This recognition highlights WuXi AppTec's integrated CRDMO model, which enhances drug development and delivery. The award underscores the company's commitment to innovation and operational excellence, supporting global pharmaceutical advancements.
Shanghai Fosun Pharmaceutical's subsidiary, Shanghai Zhaohui Pharmaceutical, has received approval for its drug registration application for Polyethylene Glycol (3350) Electrolytes Powder from the National Medical Products Administration. This drug targets chronic constipation and represents a significant R&D investment of RMB6.21 million. The approval could strengthen Fosun Pharma's market position in China. The latest analyst rating for Fosun Pharma's stock (HK:2196) is a Buy with a target price of HK$35.30.
